Clinical Trials

35 enrolled

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439331 2026-03-18

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439357 2026-03-18

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

4 enrolled 10 charts

BreastCNSDermatologicOther hematologic neoplasmThoracic

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Phase 1/2 Terminated

8 enrolled 13 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT05436418 2026-03-18

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

260 enrolled

Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06904066 2026-03-18

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

LymphoidMyeloidOther hematologic neoplasm

86 enrolled

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07220616 2026-03-18

A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies

420 enrolled

Hematologic Neoplasms

NCT04634552 2026-03-17

MonumenTAL-1

Other hematologic neoplasmPlasma cell

510 enrolled 1 FDA

Multiple Myeloma, Hematologic Neoplasms

NCT03486873 2026-03-16

MK-3475-587

Phase 3 Recruiting

3,500 enrolled

Hematologic Neoplasms

NCT03838926 2026-03-16

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

42 enrolled

Neoplasms, Recurrence, Hematologic Neoplasms

NCT04588922 2026-03-16

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

160 enrolled

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04728893 2026-03-16

MK-1026-003

490 enrolled

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Hematologic Neoplasms

NCT04926285 2026-03-16

VEN-OM

Phase 1 Completed

6 enrolled

Recurrence, Hematologic Neoplasms

NCT01606033 2026-03-13

IPSY

Phase NA Completed

125 enrolled

Neoplasm Metastasis, Hematologic Neoplasms

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Other hematologic neoplasmSarcoma

420 enrolled

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

NCT06377059 2026-03-13

Early Detection of Complications During Immunotherapy for Haematological Malignancy

100 enrolled

Phase 1/2 Active not recruiting

Cytokine Release Syndrome, Hematologic Neoplasms

NCT03145181 2026-03-12

MajesTEC-1

302 enrolled 1 FDA

Phase 1 Active not recruiting

Hematologic Neoplasms

NCT03399799 2026-03-12

MonumenTAL-1

279 enrolled 1 FDA

Hematologic Neoplasms

NCT04557098 2026-03-12

MajesTEC-1

194 enrolled 1 FDA

Hematologic Neoplasms

NCT04565665 2026-03-10

Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia

70 enrolled

COVID-19, Hematologic Neoplasms

NCT07173166 2026-03-10

CARE-T

100 enrolled

Motor Activity, Hematologic Neoplasms, Neurotoxicity Syndromes

NCT07257419 2026-03-10

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

60 enrolled

Phase NA Active not recruiting

Recurrence, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07456982 2026-03-09

The Effect of Relaxation Breathing Exercise on Chemotherapy Induced Nausea and Vomiting

68 enrolled

Phase NA Not yet recruiting

Nausea, Vomiting, Hematologic Neoplasms

NCT07456189 2026-03-06

The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary Infiltrating

20 enrolled

Hematologic Neoplasms

NCT02464696 2026-03-05

Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

256 enrolled

Phase NA Active not recruiting

Hematologic Neoplasms

NCT04914338 2026-03-05

A Multidisciplinary Approach to Improve the Health of Older Adults With Blood Cancers After Stem Cell Transplantation

40 enrolled

Hematologic Neoplasms

NCT04984551 2026-03-05

Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia

312 enrolled

Hematologic Neoplasms

NCT07006506 2026-03-05

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

46 enrolled

Graft vs Host Disease, Hematologic Neoplasms

NCT02333162 2026-03-04

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

30 enrolled

Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04939090 2026-03-04

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Phase 3 Recruiting

360 enrolled

Anorexia, Hematologic Neoplasms

NCT05866757 2026-03-04

Discontinuation Study

Other hematologic neoplasmPlasma cell

70 enrolled

Multiple Myeloma, Neoplasms, Hematologic Neoplasms

NCT05887167 2026-03-04

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

20 enrolled

Multiple Myeloma, Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07044544 2026-03-04

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

MyeloidOther hematologic neoplasm

20 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07297160 2026-03-04

CALySSEY

Phase 1 Not yet recruiting

88 enrolled

GenitourinaryLymphoidOther hematologic neoplasmPlasma cellSarcoma

Kidney Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT06910969 2026-03-03

HORIZONS

350 enrolled

Graft vs Host Disease, Hematologic Diseases, Neoplasms, Neoplasms by Site, Hematologic Neoplasms

NCT07285668 2026-03-03

Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies

38 enrolled

Hematologic Neoplasms

NCT05873205 2026-03-02

Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation

12 enrolled

Phase 2 Not yet recruiting

Hematologic Neoplasms

NCT07441967 2026-03-02

The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation

44 enrolled

Phase 3 Active not recruiting

Hematologic Neoplasms

NCT04089358 2026-02-27

Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study

387 enrolled

Hematologic Neoplasms

NCT04438382 2026-02-27

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Phase 2 Terminated

1 enrolled 1 chart